Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Medroxyprogesterone
Drug ID BADD_D01365
Description Not Available
Indications and Usage Not Available
Marketing Status Not Available
ATC Code G03AC06; G03DA02; L02AB02
DrugBank ID Not Available
KEGG ID D08166
MeSH ID D008525
PubChem ID 10631
TTD Drug ID D0I2SD
NDC Product Code 54348-805; 0009-0067
UNII HSU1C9YRES
Synonyms Medroxyprogesterone | (6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione | Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6alpha)- | 17 alpha-Hydroxy-6 alpha-Methylprogesterone | 17 alpha Hydroxy 6 alpha Methylprogesterone | Methylhydroxyprogesterone | Adgyn Medro
Chemical Information
Molecular Formula C22H32O3
CAS Registry Number 520-85-4
SMILES CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CC(=O)CC4)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Loss of libido19.08.03.003--Not Available
Mass08.03.05.003--Not Available
Menometrorrhagia21.01.03.001--Not Available
Menopausal symptoms21.02.02.002--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Myocardial infarction02.02.02.007; 24.04.04.009--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oligomenorrhoea21.01.02.004; 05.05.01.011--Not Available
Optic neuritis17.04.05.001; 06.04.08.002; 10.02.01.097--Not Available
Osteoporosis15.02.03.002; 14.04.04.002--
Osteoporotic fracture15.08.02.007; 14.04.04.007; 12.04.02.005--Not Available
Ovarian cancer21.11.01.003; 16.12.04.001--Not Available
Pain in extremity15.03.04.010--
Pancreatitis07.18.01.001--
Paraesthesia23.03.03.094; 17.02.06.005--
Paralysis17.01.04.004--Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Pharyngitis11.01.13.003; 22.07.03.004; 07.05.07.004--
Premenstrual syndrome17.14.01.019; 21.01.01.007; 19.04.02.009--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene